Company: TYRA
Filing Date: 2025-04-18
Form Type: DEF 14A
Source: 0001193125-25-085709
Chunk: 23

Company: Tyra Biosciences, Inc.
Filing Date: 2025-04-18
Form: DEF 14A
Chunk 23
---
 Committee recommended to the Board that the audited financial statements be included in the Company’s Annual Report on Form 10-Kfor the fiscal year ended December 31, 2024. The Audit Committee and the Board also have recommended, subject to stockholder approval, the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2025. This report of the Audit Committee is not “soliciting material,” shall not be deemed “filed” with the SEC and shall not be incorporated by reference by any general statement incorporating by reference this proxy statement into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent that we specifically incorporate this information by reference, and shall not otherwise be deemed filed under such acts. The foregoing report has been furnished by the Audit Committee. Respectfully submitted,

| Audit Committee          |
| Rehan Verjee, Chair      |
| Robert More              |
| Melissa McCracken, Ph.D. |

Executive Officers The following table identifies our executive officers as of April 4, 2025:

| Name                 |     | Age |     | Position                                        |
| Todd Harris, Ph.D.   |     |  45 |     | President, Chief Executive Officer and Director |
| Daniel Bensen        |     |  50 |     | Chief Operating Officer                         |
| Alan Fuhrman         |     |  68 |     | Chief Financial Officer                         |
| Douglas Warner, M.D. |     |  53 |     | Chief Medical Officer                           |

**The following is biographical information for our executive officers other than Dr. Harris, whose biographical information is included under “Continuing Members of the Board of Directors”. Daniel Bensenhas served as our Chief Operating Officer since November 2018 and previously also served as a member of our Board from November 2018 to January 2020. Prior to co-foundingTyra with Dr. Harris, Mr. Bensen served as Head of Immunology and Protein Chemistry at Cidara Therapeutics, Inc. from March 2014 until November 2018. Before Cidara, Mr. Bensen served as Principal Scientist, Protein Chemistry and Structural Biology at Trius Therapeutics, Inc. from March 2007 until February 2014. Mr. Bensen holds